Kallikrein–kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys

In a subgroup of hereditary angioedema (HAE) patients with normal C1-esterase inhibitor levels, HAE is caused by a Thr309Lys mutation in the coagulation factor XII (F12) gene. The aim of this study was to examine elements of the kallikrein–kinin system (‘contact system’) and the downstream-linked coagulation, complement and fibrinolytic systems in the plasma of six patients with HAE caused by the Thr309Lys mutation and healthy probands. Blood samples were taken from participants during the symptom-free interval between attacks. Samples were analyzed for activity and concentrations of components of the kallikrein–kinin system and linked enzyme systems. The mean FXII clotting activity was 90% in patients with the FXII mutation, and the concentration of FXIIa was 4.1 ng/ml; this did not differ from healthy probands. Mean prekallikrein amidolytic activity and high-molecular-weight kininogen clotting activity were 130 and 144%, respectively, both higher than in healthy probands. The mean kallikrein-like activity of the HAE patients was 11.4 U/l and did not differ from healthy probands. There was no difference in FXII surface activation by silicon dioxide or in kallikrein-like activity with and without activation by dextran sulfate. Contrary to the results of a recently published study, no indication that the Thr309Lys mutation causes a ‘gain-of-function’ of FXIIa was observed in this investigation.

[1]  K. Bork,et al.  Treatment of skin swellings with C1‐inhibitor concentrate in patients with hereditary angio‐oedema , 2008, Allergy.

[2]  C. Bell,et al.  First molecular confirmation of an Australian case of type III hereditary angioedema. , 2008, Pathology.

[3]  S. Cichon,et al.  Hereditary angioedema with normal C1 inhibitor gene in a family with affected women and men is associated with the p.Thr328Lys mutation in the F12 gene. , 2007, The Journal of allergy and clinical immunology.

[4]  P. Schlattmann,et al.  Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). , 2007, The Journal of allergy and clinical immunology.

[5]  S. Cichon,et al.  A case of hereditary angio‐oedema type III presenting with C1‐inhibitor cleavage and a missense mutation in the F12 gene , 2007, The British journal of dermatology.

[6]  S. Cichon,et al.  Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. , 2006, American journal of human genetics.

[7]  K. Bork.  Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. , 2006, Immunology and allergy clinics of North America.

[8]  K. Bork,et al.  Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. , 2006, Biochemical and biophysical research communications.

[9]  K. Bork,et al.  Hereditary angioedema: new findings concerning symptoms, affected organs, and course. , 2006, The American journal of medicine.

[10]  K. Bork,et al.  Hereditary angioneurotic oedema and blood-coagulation: Interaction between C1-esterase-inhibitor and the activation factors of the proteolytic enzyme systems , 1983, Klinische Wochenschrift.

[11]  A. Kaplan,et al.  Formation of bradykinin: a major contributor to the innate inflammatory response. , 2005, Advances in immunology.

[12]  A. Kaplan,et al.  High molecular weight kininogen and factor XII binding to endothelial cells and astrocytes , 2003, Thrombosis and Haemostasis.

[13]  I. Schousboe.  Binding of activated Factor XII to endothelial cells affects its inactivation by the C1-esterase inhibitor. , 2002, European journal of biochemistry.

[14]  A. Schmaier,et al.  Identification and Characterization of Prolylcarboxypeptidase as an Endothelial Cell Prekallikrein Activator* , 2002, The Journal of Biological Chemistry.

[15]  A. Schmaier,et al.  Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. , 2002, Blood.

[16]  A. Davis,et al.  Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. , 2002, The Journal of clinical investigation.

[17]  A. Kaplan,et al.  Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  K. Binkley,et al.  Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. , 2000, The Journal of allergy and clinical immunology.

[19]  K. Bork,et al.  Hereditary angioedema with normal C1-inhibitor activity in women , 2000, The Lancet.

[20]  K. Bork,et al.  Asphyxiation by laryngeal edema in patients with hereditary angioedema. , 2000, Mayo Clinic proceedings.

[21]  M. Cicardi,et al.  Plasma bradykinin in angio-oedema , 1998, The Lancet.

[22]  C. Hack,et al.  Structure/Function Analysis of Human Factor XII Using Recombinant Deletion Mutants , 1996 .

[23]  C. Hack,et al.  Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces. , 1996, European journal of biochemistry.

[24]  S. Reddigari,et al.  Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. , 1993, The Journal of biological chemistry.

[25]  M. Cicardi,et al.  Hereditary and Acquired C1‐Inhibitor Deficiency: Biological and Clinical Characteristics in 235 Patients , 1992, Medicine.

[26]  P. Kuna,et al.  Generation of vasoactive peptide bradykinin from human umbilical vein endothelium-bound high molecular weight kininogen by plasma kallikrein. , 1992, Blood.

[27]  John D Lambris,et al.  Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies. , 1989, The Journal of clinical investigation.

[28]  N. Hoem,et al.  Assay of kallikrein inhibitors and levels of acetone-activated kallikrein in plasma specimens from reactors to dextran or to contrast media. , 1986, International journal of tissue reactions.

[29]  R. Colman,et al.  Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties. , 1985, Blood.

[30]  R. G. Fraser,et al.  Hereditary cardiovascular dysplasia. A form of familial cardiomyopathy. , 1961, The American journal of medicine.